ASCO 2024: Phase II Survival Update of Palbociclib Plus Exemestane in Metastatic Breast Cancer

By: Sarah Lynch
Posted: Monday, June 17, 2024

A group of researchers conducted the Young-PEARL study, which analyzed the efficacy of the combination of exemestane and the CDK4/6 inhibitor palbociclib with ovarian function suppression compared with capecitabine in premenopausal patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. Yeon Hee Park, MD, PhD, of Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues presented updated survival results from this trial at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract LBA1002).

“[The] Young-PEARL study showed exemestane plus palbociclib with ovarian function suppression improves efficacy compared with capecitabine in terms of progression-free survival, which did not lead to an overall survival benefit for patients with premenopausal HR-positive/HER2-negative metastatic breast cancer (median follow-up, 54.8 months),” the authors reported.

The study included premenopausal women who experienced a relapse or progression of HR-positive, HER2-negative breast cancer during previous tamoxifen treatment. The study allowed for one line of previous chemotherapy. Patients were assigned to either exemestane plus palbociclib with ovarian function suppression or capecitabine, and data were analyzed from 174 patients.

The median progression-free survival was 19.5 months with exemestane plus palbociclib and ovarian function suppression and 14.0 months with capecitabine. The median overall survival was 54.8 months with the exemestane combination and 57.8 months with capecitabine. With longer follow-up, they noted, the overall safety profiled of the investigation combination continued to be manageable.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.

2024 ASCO Annual Meeting

---